3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Neoplasms
3
Non-small Cell Lung Cancer Metastatic
2
Stomach Neoplasms
1
Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
1
Non-squamous Non-small Cell Lung Cancer
1
Lung Neoplasms
1
Breast Neoplasms
1
Breast Cancer Metastatic
1
Adenocarcinoma Gastric
1
Interventions
pembrolizumab
4
Pemetrexed
4
Carboplatin
4
Gemcitabine
3
Bevacizumab
3
tusamitamab ravtansine
2
Vinorelbine
2
Ramucirumab
2
Erlotinib Hydrochloride
2
Docetaxel
2
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
2
vistusertib
1
vandetanib
1
telomerase reverse transcriptase p572Y, human
1
spartalizumab
1
sotorasib
1
sintilimab
1
olaparib
1
necitumumab
1
icotinib
1
durvalumab
1
dacomitinib
1
capivasertib
1
aumolertinib
1
Radiosurgery
1
Platinum
1
Paclitaxel
1
MLN 8237
1
LY3023414
1
Injections
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Non-small Cell Lung Cancer Metastatic
×
tusamitamab ravtansine
×
Clear all
NCT04154956
2026-05-18
CARMEN-LC03
Sanofi
Phase 3
Terminated
389 enrolled
16 charts
NCT04394624
2025-06-06
CARMEN-LC04
Sanofi
Phase 2
Terminated
31 enrolled
22 charts